Mount Sinai Health System will implement SOPHiA GENETICS' AI-powered SOPHiA DDM Platform to enhance its cancer research and genomic testing capabilities, the companies announced from the American Association for Cancer Research Annual Meeting.

Mount Sinai, a National Cancer Institute-designated Comprehensive Cancer Center in New York City that treats more than 4,000 oncology patients annually, will use the platform to strengthen next-generation sequencing capabilities for blood cancers and solid tumors. The system is designed to detect and interpret genomic variants while reducing manual interpretation time.

SOPHiA GENETICS (NASDAQ: SOPH) operates a cloud-native healthcare technology platform that analyzes genomic data and generates insights for hospitals, laboratories, and pharmaceutical institutions globally. The company serves more than 990 institutions worldwide through its decentralized platform.

"The collaboration between Mount Sinai and SOPHiA GENETICS reinforces our commitment to scientific innovation by integrating powerful digital tools into our workflows to support high-quality, data-driven cancer care," said Jane Houldsworth, Director of Molecular Oncology Pathology at Mount Sinai Health System. "Leveraging SOPHiA DDM has enabled us to reduce hands-on analysis time and improve our testing turnaround times, enabling our clinicians to provide better patient care."

John Carey, Managing Director for North America at SOPHiA GENETICS, noted that Mount Sinai was recently ranked first globally among healthcare institutions in the Nature AI Index. Mount Sinai's molecular pathology team will use the platform to consolidate critical steps in the analysis pipeline and optimize laboratory resources.

The collaboration was announced at the AACR meeting in San Diego, with SOPHiA GENETICS exhibiting at the conference through April 22, 2026.